(function(){ var content_array=["

About Colorectal Cancer<\/strong> <\/p>\r\n

Colorectal cancer (CRC) is the second most common cancer worldwide, with an estimated incidence of more than 1.36 million new cases annually.[3] Approximately 694,000 deaths from CRC occur every year, accounting for 8.5% of all cancer deaths and making it the fourth most common cause of death from cancer.[3] Almost 55% of CRC cases are diagnosed in developed regions of the world, and incidence and mortality rates are substantially higher in men than in women.[3]<\/p>\r\n

Note to Editors:<\/strong> <\/p>\r\n

Please click here<\/a> to view the multimedia release which includes mCRC biomarker videos and additional information.<\/p>\r\n

Additional information resources for media on mCRC are available online from: http:\/\/www.globalcancernews.com\/<\/a><\/p>\r\n

References<\/strong> <\/p>\r\n

\r\n
Sanoff HK, et al. J Clin Oncol 2008;26(35):5721-7. <\/li>\r\n
Van Cutsem E, et al. Ann Oncol 2010;21(Suppl 5):v93-7. <\/li>\r\n
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http:\/\/globocan.iarc.fr\/<\/a>. Last accessed March 2014. <\/li>\r\n<\/ol>\r\n
About Merck Serono<\/strong> <\/p>\r\n
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.<\/p>\r\n
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.<\/p>\r\n
For more information, please visit http:\/\/www.merckserono.com\/<\/a>.<\/p>\r\n
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http:\/\/www.merckgroup.com\/subscribe<\/a> to register online, change your selection or discontinue this service.<\/p>\r\n
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of 11.1 billion euro in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges.<\/p>\r\n
Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.<\/p>\r\n
Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.<\/p>\r\n
Contact:
Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt
Germany
Hotline +49(0)6151-72-5000
http:\/\/www.merckgroup.com\/<\/a>

Merck Serono is a division of Merck
http:\/\/www.merckserono.com\/<\/a>
Raphaela Farrenkopf
Phone +49-6151-72-2274<\/p>\r\n
Video:
http:\/\/www.multivu.com\/mnr\/7140053-merck-serono-metastatic-colorectal-cancer<\/a><\/p>"]; $("#dvExtra").html(content_array[0]);})();